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Abstract
Objectives. Dysregulated signal transduction and activator of transcription-3 (STAT3) signalling in CD4+ T cells has
been proposed as an early pathophysiological event in RA. We sought further evidence for this observation, and to
determine its clinical relevance.
Methods. Microarray technology was used to measure gene expression in purified peripheral blood CD4+ T cells from
treatment-naı¨ve RA patients and disease controls newly recruited from an early arthritis clinic. Analysis focused on 12
previously proposed transcripts, and concurrent STAT3 pathway activation was determined in the same cells by flow
cytometry. A pooled analysis of previous and current gene expression findings incorporated detailed clinical parameters
and employed multivariate analysis.
Results. In an independent cohort of 161 patients, expression of 11 of 12 proposed signature genes differed signifi-
cantly between RA patients and controls, robustly validating the earlier findings. Differential regulation was most pro-
nounced for the STAT3 target genes PIM1, BCL3 and SOCS3 (>1.3-fold difference; P < 0.005), each of whose
expression correlated strongly with paired intracellular phospho-STAT3. In a meta-analysis of 279 patients the same
three genes accounted for the majority of the signature’s ability to discriminate RA patients, which was found to be
independent of age, joint involvement or acute phase response.
Conclusion. The STAT3-mediated dysregulation of BCL3, SOCS3 and PIM1 in circulating CD4+ T cells is a discrim-
inatory feature of early RA that occurs independently of acute phase response. The mechanistic and functional impli-
cations of this observation at a cellular level warrant clarification.
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Rheumatology key messages
. Three STAT3-regulated genes discriminate RA independently of clinical parameters in early arthritis CD4+
lymphocytes.
. The mechanistic relevance of these genes’ activation amongst early RA CD4+ lymphocytes awaits clarification.
Introduction
RA is a chronic disease of immune dysregulation the
pathogenesis of which remains incompletely understood
[1]. An orchestrating role for CD4+ T cells is suggested by
a number of lines of evidence, including accumulating
data from genetic association studies [2, 3], analyses of
diseased synovia [4] and the observed therapeutic effi-
cacy of co-stimulation blockade [5]. We previously identi-
fied a 12-gene CD4+ T cell expression signature in early
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arthritis patients that predicted a diagnosis of RA [6]. This
signature comprised an over-representation of genes
regulated by signal transduction and activator of tran-
scription-3 (STAT3), each of whose expression correlated
with paired serum levels of IL-6, itself a prominent inducer
of STAT3 signalling [7]. Using flow cytometry we recently
confirmed the importance of IL-6-mediated STAT3 activa-
tion in CD4+ T cells (in contrast to other circulating cyto-
kines and leukocytes) as an early event in the clinical
phase of RA, and suggested its potential value as a diag-
nostic biomarker [8].
Aberrant STAT3 signalling has a well-documented role
in tumorigenesis via induction of pro-survival and cell
cycle pathways [911]. Our observations add to accumu-
lating evidence that analogous mechanisms of STAT3
dysregulation might sustain autoimmunity [12, 13].
Through a more sophisticated understanding of IL-6/
STAT3 signalling at a cellular level, therapies that go
beyond generic blockade of the IL-6 inflammatory cas-
cade, instead targeting disease-specific mechanisms,
may be uncovered [14].
The current investigation sought to validate the rele-
vance of our previously described CD4+ T cell gene sig-
nature in a distinct early arthritis cohort. In particular, we
determined the extent to which expression of STAT3-
regulated genes was independently associated with a
diagnosis of RA when considered alongside clinical par-
ameters such as inflammation.
Methods
Patients
During 201213, consecutive patients were recruited from
the Newcastle Early Arthritis Cohort, which has been
described in detail elsewhere [6, 15, 16], and peripheral
blood was obtained prior to commencement of therapy.
Initial diagnoses were validated at follow-up visits over a
median period of 20 months (range 1325) as described
[8], and with reference to 2010 ACR/EULAR classification
criteria for RA [17]. All patients gave written, informed con-
sent for inclusion into the study, which was approved by
the local Regional Ethics Committee.
Twelve-gene expression signature measurement in
CD4+ T cells of the independent cohort
Total RNA was extracted from CD4+ T cells positively se-
lected from monocyte-depleted whole blood within 4 h of
blood draw as previously described [6]. cRNA generated
from 250 ng total RNA (Illumina TotalPrep RNA
Amplification Kit) was hybridized to the Illumina Human
HT12v4 BeadChip (Illumina, San Diego, CA, USA). After
quality control using established methods previously out-
lined [6], data relating exclusively to the 12 signature
genes previously identified [6] were extracted for detailed
analysis. Expression data used for this experiment are
available in the Gene Expression Omnibus database
(GEO: http://www.ncbi.nlm.nih.gov/geo; accession
number GSE80513). Since the HT12v4 BeadChip annota-
tion differed slightly from the WG6v3 array used for our
original work, unique Illumina NuId references were used
instead to map probes of identical sequence for this
purpose.
Flow cytometric determination of STAT3 pathway
activation in CD4+ T cells
Phosflow cytometry was performed on freshly drawn, un-
stimulated whole blood obtained contemporaneously with
that used for CD4+ T cell RNA extraction. Anti-CD4-APC-
eFluor 780 (SK3) (eBioscience Ltd, Hatfield, UK),
anti-Stat3 (pY705)-Alexa Fluor 647 (4/P-STAT3) and anti-
CD3-Pacific Blue (UCHT1) (both BD Biosciences, Oxford,
UK) were used along with appropriate buffers and controls
in the staining protocol as previously described [8]. Data
were collected on a BD FACSCanto II (BD Biosciences,
Oxford, UK) and analysed using FlowJo (Treestar,
Ashland, OR, USA).
Combined cohort microarray analysis
Since baseline and follow-up diagnostic classification of
patients in the previously described cohort [6] was under-
taken with reference to the 1987 ACR criteria [18], retro-
spective application of the 2010 ACR/EULAR
classification criteria was applied [17], so that both co-
horts were similarly classified. Thirteen of 62 patients pre-
viously classified at baseline with undifferentiated arthritis
became 2010-RA, and 6 of 47 1987-RA patients did not
fulfil the 2010 criteria. Next, a de novo pipeline for the
normalization and quality control of independently derived
raw microarray datasets from the previous and current
patient cohorts (GEO accession numbers GSE20098 and
GSE80513, respectively) was employed as previously
described, demonstrably accounting for anticipated
batch effects [19].
Statistical analysis
Hierarchical clustering (Euclidian distance metric; Ward’s
linkage method) was performed and visualized in R pro-
gramming environment (https://r-project.org).
MannWhitney U and Kruskal Wallis tests were used
for two-group and multiple group univariate analyses, re-
spectively, along with chi-squared (2) and Komogorov-
Smirnov tests as indicated in the text. Bivariate correl-
ations were determined using Spearman’s Rho, and lo-
gistic regression was used for multivariate analyses with
validated diagnostic outcome as the dependent variable,
and independent variables as detailed in the text.
Receiver-operating characteristic curves for competing
logistic regression models were constructed and differ-
ences in their areas under the curve compared using
t-tests. In addition, scatterplots overlaid with non-
parametric density plots [20] were used to depict
separation of comparator groups attributable to normal-
ized gene expression, using SAS Institute JMP statistical
visualization software (version 13; Cary, NC, USA).
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Results
Baseline clinical characteristics of newly recruited
patients
Some 161 early arthritis patients were enrolled into the
study, of whom 47 (29%) were diagnosed with RA and
the remainder with alternative diagnoses; their baseline
clinical characteristics are summarized in Table 1. Early
RA patients differed, on average, from other early arthritis
clinic attendees by a higher acute phase response, more
swollen and tender joints, circulating autoantibodies (RF
ACPA) and older age.
Independent validation of STAT3-regulated CD4+
T cell signature in early RA
In our independent cohort of 161 treatment-naı¨ve early
arthritis clinic attendees, significant differences in normal-
ized expression were seen for 11 of the 12 previously
identified signature genes between RA and non-RA
CD4+ T cells (Table 2). Only thee (PIM1, BCL3 and
SOCS3) achieved the 1.2-fold difference between com-
parator groups set as a threshold in our original study
[6], but they did so comfortably with >1.3-fold differences
being observed in each case (Table 2 and Fig. 1AC).
Indeed, it was notable that these three genes were
ranked amongst the top 25 differentially expressed by
fold-difference out of a total of 30 458 non-redundant, fil-
tered probes in the source microarray dataset, something
that would be highly unlikely to have occurred by chance
(P = 9.8  1010, one-sample Kolmogorov-Smirnov test).
The three highlighted genes are known to be regulated by
STAT3 [2123]. We therefore hypothesized that their nor-
malized expression would in turn depend upon constitu-
tive STAT3 phosphorylation in CD4+ T cells, as measured
using flow cytometry of contemporaneously obtained
fresh blood samples. Intracellular phospho-STAT3 meas-
urements indeed correlated strikingly with paired BCL3,
SOCS3 and PIM1 gene expression in ex vivo CD4+ T
cells of early arthritis patients (Fig. 1DF), but not with
that of other genes in the signature such as PDCD1 or
IGFL2, which are not known to be induced by STAT3 (sup-
plementary Fig. S1, available at Rheumatology online).
These data confirm the importance of STAT3 signalling
as a mediator of BCL3, SOCS3 and PIM1 gene induction
in early RA.
Twelve-gene signature’s ability to discriminate early
RA in combined cohort accounted for by a three-gene
subset
Our previously described 12-gene CD4+ T cell signature
was originally identified in untreated early RA patients
defined prior to the publication of modified classification
criteria for the condition. In our independent RA cohort,
defined under the new classification system, a subset of
three genes (BCL3, SOCS3 and PIM1) was clearly up-regu-
lated. To investigate whether this held true following diag-
nostic re-classification of the previous cohort, and to
increase the statistical power of our study, a pooled ana-
lysis of microarray data was carried out. Some 101 of 279
(36%) in the combined cohort were diagnosed with RA,
and these individuals were again distinguishable from
other early arthritis clinic attendees at baseline by their
TABLE 1 Baseline clinical characteristics of patients according to diagnosis
Diagnosisa
P-valuebRA (n= 47) Non-RA (n= 114)
Age, years 60 (2187) 51 (1792) <0.001
% Female 74 68 ns
Symptom duration 12 (252) 12 (2>52) ns
TJC28 6 (120) 2 (025) 0.001
SJC28 1 (117) 0 (09) 0.002
CRP, g/l 10 (<566) 5 (<5189) 0.005
ESR 21 (486) 9 (1113) 0.004
%RF+ 64 10 <0.001
%ACPA+ 64 0 <0.001
DAS28 4.32 (2.247.15) n/a n/a
Non-RA diagnoses,
number (% of 114) PsA, 20 (17)
Other SpA, 18 (16)
Crystal, 10 (9)
Other
IA, 8 (7)
OA, 25 (22)
Other non-
IA, 33 (29)
Values are median (range) unless otherwise stated. aBaseline diagnosis was confirmed at median 20 months (range 1325).
bMannWhitney U test or chi-squared test with Yates’ continuity correction for continuous and dichotomous data respectively.
TJC: tender joint count; SJC: swollen joint count; ns: not significant; n/a: not applicable; IA: inflammatory arthritis.
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FIG. 1 Expression of STAT3-regulated genes in circulating CD4+ lymphocytes of an independent early arthritis cohort
(AC) Normalized gene expression of three STAT3-regulated genes in circulating CD4+ T cells of an independent early
arthritis cohort of 161 patients presenting with RA or other arthritides (Non-RA). MannWhitney U tests used to determine
P-values; FC denotes fold-change. (DF) Bivariate correlation between the same genes’ normalized expression and
pSTAT3 measurements in paired circulating CD4+ T cells of early arthritis clinic attendees. Spearman’s Rho correlation
coefficients and associated P-values are depicted. STAT3: signal transduction and activator of transcription-3; pSTAT:
phospho-STAT3.
TABLE 2 Normalized expression values of indicated transcripts in early arthritis patient diagnostic groups of the
independent cohort
Gene Normalized expressiona
Symbol RefSeq Illumina Probe ID RA (n= 47) Non-RA (n= 114) Fold-changeb P-valuec
BCL3 NM_005178 ILMN_1710514 867 585 1.48 <0.001
PIM1 NM_002648 ILMN_1815023 3567 2633 1.35 <0.001
SOCS3 NM_003955 ILMN_1781001 850 614 1.38 0.004
LDHA NM_005566 ILMN_1807106 7493 6572 1.14 <0.001
GPRIN3 CR743148d ILMN_1901616 377 322 1.17 0.004
MUC1 NM_001044391 ILMN_1756992 310 283 1.10 0.013
PDCD1 NM_005018 ILMN_1806725 168 159 1.06 0.029
SBNO2 NM_014963 ILMN_1808811 193 180 1.07 0.011
IGFL2 NM_001002915 ILMN_1790227 142 135 1.05 0.017
LOC731186 XM_001128760 ILMN_1900154 148 145 1.02 0.033
CMAHP NR_002174 ILMN_1704084 222 217 1.02 ns
NOG NM_005450 ILMN_1652287 143 150 1.05 0.007
RefSeq accession numbers and Illumina probe IDs are given (see supplementary Table S1, available at Rheumatology online
for probe sequences). aMedian normalized gene expression values presented. bLinearized fold-change relative to non-RA
group given. cMannWhitney U test. dTranscript CR743148 has been retired from the National Center for Biotechnology
Information, but the expressed sequence tag corresponds to splice variant(s) within the GPRIN3 gene (chromosome 4.90).
Genes demonstrating >1.2-fold differences indicated in boldface. ns: not significant.
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older age, increased number of tender and swollen joints,
and higher acute phase responses; detailed characteristics
of the combined cohort are summarized in supplementary
Table S1, available at Rheumatology online. Fig. 2A depicts
the results of hierarchical clustering based on the 12-gene
signature in the combined cohort, discriminating a subset
of individuals enriched for a diagnosis of RA [includes 68/
101 (67%) RA patients in the overall population compared
with 40/178 (22%) non-RA patients; P < 0.001, 2 test].
Again, only the expression of BCL3, SOCS3 and PIM1
stood out as being >1.2-fold up-regulated in early RA on
univariate analysis of this combined cohort (supplementary
Table S2, available at Rheumatology online). Hierarchical
clustering confirmed that these three genes alone ac-
counted for the majority of the previously noted clustering
effect, once more discriminating a subgroup that was sig-
nificantly enriched for RA (2 P < 0.001; Fig. 2B). Moreover,
segregation of RA patients from disease controls is evident
when representing the data in 2D space according to their
normalized expression (Fig. 2C). These data indicate that
BCL3, SOCS3 and PIM1 account for the majority of the
previously described 12-gene signature’s discriminatory
ability with respect to a diagnosis of RA in the setting of
an early arthritis clinic.
Association of gene expression with RA is
independent of baseline clinical parameters
Considering the potentially confounding influence of age,
swollen or tender joint count, and, in particular, acute
FIG. 2 Discriminatory utility of a proposed CD4+ lymphocyte signature is primarily accounted for by three genes
(A) Dendrogram and heat map depicting results of hierarchical clustering of 279 early arthritis patients (columns) ac-
cording to normalized expression of 12 signature genes in circulating CD4+ T cells (rows). Red dotted line identifies RA-
enriched cluster highlighted in text. (B) Analogous result as for (A), based on normalized expression levels of three-gene
signature only. (C) Scatterplots overlaid with non-parametric density plots separate RA patients and non-RA patients
based on normalized expression alone, such that the two populations in each case preferentially occupy the top right and
bottom left quadrants, respectively.
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phase response (Table 1 and supplementary Tables S1
and S3, available at Rheumatology online), we used logis-
tic regression to confirm that the up-regulation of BCL3,
PIM1 and SOCS3 observed in early RA was independent
of these clinical parameters (P < 0.05 for each gene;
Table 3). To quantify the relative additive value of a
three-gene (comprising BCL3, SOCS3 and PIM1) or 12-
gene signature over clinical parameters alone, results of
multivariate analyses summarized as composite receiver-
operating characteristic curves were compared (Fig. 3).
Hence, by including the 12-gene signature in a model
that included age, swollen joint count, tender joint count,
CRP and ESR, a statistically significant area under the
curve increase from 0.780.87 was achieved (P <
0.001). Interestingly, however, the three-gene signature
accounted for a substantial component of this effect
(area under the curve increase 0.780.83; P = 0.007).
Considered together, these findings suggest that up-regu-
lated expression of BCL3, SOCS3 and PIM1 in circulating
CD4+ T cells of early RA patients is independent of po-
tentially confounding clinical parameters, and accounts
for much of the previously described 12-gene signature’s
discriminatory ability for early RA.
Discussion
In this validation study, we confirmed the ability of our
previously proposed CD4+ T cell gene expression signa-
ture to identify RA patients amongst unselected, treat-
ment-naı¨ve early arthritis clinic attendees. Normalized
gene expression differed significantly between RA
patients and disease controls for 11 out of the 12 signa-
ture genes, but the fold-changes were most striking for
BCL3, PIM1 and SOCS3. Each of these genes is known
to be regulated by STAT3, and their expression correlated
significantly with paired CD4+ T cell phospho-STAT3
levels. Indeed, hierarchical clustering suggested that the
ability of the 12-gene signature to discriminate RA pa-
tients in this replication cohort was almost entirely ac-
counted for by these three genes alone. The
reproducibility of this component of the original gene sig-
nature in two independent studies separated by 5 years is
remarkable given the heterogeneity of the patient popula-
tion presenting to early arthritis clinics. Furthermore, the
signature is robust to replacement of 1987 ACR classifi-
cation criteria [18] used to define RA in our previous ana-
lysis with updated criteria developed for use specifically in
the setting of early disease [17]. Finally, our analysis
demonstrated that the associations of BCL3, PIM1 and
SOCS3 gene expression with diagnostic outcome are in-
dependent of clinical parameters such as age and sys-
temic inflammation. Rather than being mere bystander
phenomena, our data could indicate a direct role for
STAT3-regulated gene induction in RA pathogenesis, for
example via altered T cell effector function. This possibility
remains the subject of ongoing investigation.
A growing body of evidence now highlights IL-6-
mediated dysregulation of CD4+ T cell STAT3 signalling
during RA development [24, 25]. Amongst RA patients
who experience good therapeutic responses to the anti-
IL-6 receptor monoclonal antibody tocilizumab, concur-
rent down-regulation of STAT3-regulated genes by
TABLE 3 Summaries of logistic regression outputs in respect of RA vs non-RA diagnoses
B SE Wald df P-value Exp[B] (95% CI)
BCL3 0.001 0.001 6.964 1 0.008 1.001 (1.0001.002)
Age 0.037 0.011 11.831 1 0.001 1.034 (1.0161.059)
CRP 0.005 0.006 0.546 1 0.460 0.995 (0.9831.008)
ESR 0.007 0.007 1.001 1 0.317 1.007 (0.9931.022)
TJC28 0.034 0.020 2.967 1 0.085 1.034 (0.9951.075)
SJC28 0.227 0.059 14.860 1 <0.001 1.255 (1.1181.409)
Constant 4.399 0.728 36.494 1 <0.001 0.012
PIM1 0.000 0.000 7.996 1 0.005 1.000 (1.0001.001)
Age 0.034 0.011 10.258 1 0.001 1.034 (1.0131.056)
CRP 0.006 0.006 1.019 1 0.313 0.994 (0.9811.006)
ESR 0.008 0.007 1.203 1 0.273 1.008 (0.9941.022)
TJC28 0.036 0.020 3.320 1 0.068 1.036 (0.9971.077)
SJC28 0.214 0.058 13.621 1 <0.001 1.239 (1.1061.388)
Constant 4.512 0.734 37.843 1 <0.001 0.011
SOCS3 0.001 0.001 5.930 1 0.015 1.001 (1.0001.002)
Age 0.038 0.011 12.479 1 <0.001 1.038 (1.0171.060)
CRP 0.007 0.006 1.186 1 0.276 0.993 (0.9811.006)
ESR 0.009 0.007 1.648 1 0.199 1.009 (0.9951.024)
TJC28 0.031 0.019 2.587 1 0.108 1.032 (0.9931.072)
SJC28 0.150 0.082 3.327 1 0.068 1.162 (0.9891.365)
Constant 4.424 0.737 36.009 1 <0.001 0.012
BCL3, PIM1 and SOCS3 (boldface) are, respectively, considered as independent candidate variables alongside age, CRP,
ESR, TJC and SJC. TJC: tender joint count; SJC: swollen joint count.
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CD4+ T cells has been eloquently demonstrated—includ-
ing that of BCL3, PIM1 and SOCS3 [26]. Such data fuel
optimism that cellular biomarkers of STAT3 pathway acti-
vation might have clinical value for the development of
stratified treatment approaches [27].
Even more tantalizing is the possibility, suggested by
our data, that the identified IL-6-mediated transcriptional
programme might itself mark a molecular mechanism by
which susceptible CD4+ T cells switch to adopt a patho-
genic phenotype. Such speculation stems from a func-
tional consideration of the three component signature
genes we have identified. BCL3 is an atypical IkB family
member which has, until recently, been little studied in
human T cell biology [28, 29]. Particularly implicated in
the development of T follicular helper cells [30, 31], it ap-
pears to represent a common element upon which a
range of dysregulated cellular pathways converge [32],
and may play a role in restraining the plasticity of the
CD4+ T cell effector phenotype [33]. PIM1, one of a
family of three serine/threonine-dependent kinases, has
been implicated as an early mediator of Th1 commitment
[34]; it was recently suggested as a novel therapeutic
target in skin psoriasis [35]. SOCS3 is a negative regulator
of STAT3 signalling, and whether its up-regulation in early
RA reflects a direct failure of this regulatory system is un-
known, but it is notable that spontaneous inflammatory
arthritis develops in mice following mutation of the mol-
ecule’s IL-6 b-receptor binding site [36].
Taken together, it is of interest that the robust three-
gene CD4+ T cell signature we now validate parallels
the STAT3-dependent transcriptional pattern observed in
the malignant Se´zary cells of individuals with the leu-
kaemic variant of cutaneous T cell lymphoma, in which
up-regulated PIM1 and SOCS3 is specifically described
[37, 38]. By contrast, all three signature genes are down-
regulated in circulating CD4+ T cells of patients with latent
tuberculosis infection when compared with those with
active infection [39]. The extent to which their induction
by IL-6 promotes autoimmunity by sustaining a patho-
genic, pro-proliferative cell phenotype—indeed, whether
their modulation might favour tolerance induction—war-
rants concerted investigation. Such studies may reveal
targetable disease mechanisms relevant to autoimmune
diseases beyond RA alone.
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